Avidity Biosciences Inc
Gesloten
SectorGezondheidszorg
15.05
Overzicht
Wijziging aandelenprijs
24u
Min
15.05
Max
15.05
Inkomsten | -63M -237M |
|---|---|
Verkoop | -12M 860K |
EPS | -1.27 |
Winstmarge | -27,569.884 |
Werknemers | 511 |
EBITDA | -59M -232M |
Aanbevelingen | Neutraal |
|---|---|
12 Maanden Prognose | -0.1% downside |
Marktkapitalisatie | -9B 2.3B |
|---|---|
Vorige openingsprijs | 15.05 |
Vorige sluitingsprijs | 15.05 |
Technische score
By Trading Central
Vertrouwen
Strong Bearish Evidence
Avidity Biosciences Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Avidity Biosciences Inc Prognose
Koersdoel
By TipRanks
-0.1% neerwaarts potentieel
12 Maanden Prognose
Gemiddelde 72.75 USD -0.1%
Hoogste 75 USD
Laagste 72 USD
Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avidity Biosciences Inc - Dist. in de afgelopen 3 maanden.
Financieel
$
Over Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.